<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01567527</url>
  </required_header>
  <id_info>
    <org_study_id>31-08-250</org_study_id>
    <nct_id>NCT01567527</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety, and Tolerability of an Intramuscular Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Bipolar I Patients</brief_title>
  <official_title>52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole (OPC-14597) as Maintenance Treatment in Patients With Bipolar I Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a randomized, double-blind, placebo-controlled trial to assess the time to
      recurrence of any mood episode in subjects with bipolar I disorder who have maintained
      stability on aripiprazole IM depot for at least 8 weeks. This trial will include male and
      female subjects 18 to 65 years of age, inclusive, with a diagnosis of bipolar I disorder,
      according to DSM-IV-TR criteria and confirmed by the Mini International Neuropsychiatric
      Interview (MINI), who have experienced at least one previous manic episode of sufficient
      severity to require hospitalization and/or treatment with a mood stabilizer or antipsychotic
      agent in addition to their current manic episode. All subjects must be experiencing a manic
      episode (per DSM-IV-TR criteria) with a YMRS total score ≥ 20 at trial entry. Both inpatients
      and outpatients are eligible for this trial.

      This trial will consist of a screening phase followed by 4 treatment phases. Subjects will
      undergo screening for eligibility, followed by a conversion to oral aripiprazole monotherapy
      phase, if needed, an oral aripiprazole stabilization phase, a single-blind aripiprazole IM
      depot stabilization phase, and, a double-blind, placebo-controlled phase.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time From Randomization to Recurrence of Any Mood Episode During Double-bind Placebo-controlled Phase.</measure>
    <time_frame>Baseline of the Double-blind, Placebo-controlled Phase Up to the end of the study (Week 52).</time_frame>
    <description>This endpoint was defined as meeting any of the following criteria:
Hospitalization for any mood episode OR
Any of the following:
YMRS total score ≥ 15 OR
MADRS total score ≥ 15 OR
CGI-BP-S score &gt; 4 (overall score) OR
SAE of worsening disease (bipolar I disorder) OR
Discontinuation due to lack of efficacy or discontinuation due to an AE of worsening disease OR
Clinical worsening with the need for treatment of symptoms of an underlying mood disorder by addition of a mood stabilizer, antidepressant treatment, antipsychotic medication, or increase greater than the allowed benzodiazepine doses, or
Active suicidality, which is defined as a score of 4 or more on the MADRS item 10 OR an answer of &quot;yes&quot; on question 4 or 5 on the C-SSRS.
The time to event is presented in the following table.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Meeting Criteria for Recurrence of Any Mood Episode.</measure>
    <time_frame>Baseline of the Double-blind, Placebo-controlled Phase Up to the end of the study (Week 52).</time_frame>
    <description>To assess the proportion of subjects who met criteria for recurrence of any mood episode (manic, mixed or depressive). Hierarchical procedure was used to preserve the overall Type I error at 0.05.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Randomization to Endpoint in the CGI-BP-S (Mania) Score.</measure>
    <time_frame>Baseline of the Double-blind, Placebo-controlled Phase up to the end of the study (Week 52).</time_frame>
    <description>CGI-BP-S assessed the subject's severity of Illness (mania) based on a 7-point scale ranging from 1 (normal/ not ill at all) to 7 (very severely ill).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time From Randomization to Recurrence Defined by Hospitalization for a Mood Episode.</measure>
    <time_frame>Baseline of the Double-blind, Placebo-controlled Phase up to the end of the study (Week 52).</time_frame>
    <description>Analysis of time from randomization to recurrence defined by hospitalization for a mood episode (Double-blind, Placebo-controlled Phase efficacy sample).
Time to recurrence is presented in the following table.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">731</enrollment>
  <condition>Bipolar I Disorder</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active Comparator: Treatment of Aripiprazole IM Depot</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Comparator: Treatment of IM Depot Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intramuscular (IM) Depot Aripiprazole</intervention_name>
    <description>Formulation: Intramuscular (IM) Depot Aripiprazole Formulation 400 mg or 300 mg, once a month injection</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intramuscular (IM) Depot Placebo</intervention_name>
    <description>Formulation: Intramuscular (IM) Depot Placebo 400 mg or 300 mg, once a month injection</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Male and female subjects 18 to 65 years of age, inclusive, at time of informed
             consent.

          2. Subjects with a current diagnosis of bipolar I disorder, as defined by DSM-IV-TR
             criteria and confirmed by the MINI and a history of at least one previous manic or
             mixed episode with manic symptoms of sufficient severity to require one of the
             following interventions: hospitalization and/or treatment with a mood stabilizer,
             and/or treatment with an antipsychotic agent, in addition to their current manic
             episode. &quot;Require&quot; is defined as an intervention that occurred rather than one that
             was recommended. Rapid cyclers with 8 or fewer episodes in the previous year will be
             included.

          3. Subjects currently experiencing a manic episode with a YMRS total score of ≥20 at the
             Screening Visit.

          4. Subjects can have an inpatient or outpatient status prior to entry into Phase C (IM
             depot stabilization).

          5. In the investigator's opinion, subjects who are able to understand the nature of the
             trial and follow protocol requirements, including the prescribed dosage regimens,
             tablet ingestion, aripiprazole IM depot injection, and discontinuation of prohibited
             concomitant medications; who can read and understand the written word in order to
             complete subject-reported outcomes measures; and who can be reliably rated on
             assessment scales.

        Key Exclusion Criteria:

          1. Subjects with a current Axis I (DSM-IV-TR) diagnosis other than bipolar I disorder.

          2. Subjects who have NOT experienced at least one previous manic or mixed episode with
             manic symptoms of sufficient severity to require one of the following interventions:
             hospitalization and/or treatment with a mood stabilizer, and /or treatment with an
             antipsychotic agent, excluding their current manic episode. &quot;Require&quot; is defined as a
             intervention that occurred rather than one that was recommended.

          3. Subjects with bipolar I disorder who are considered resistant/refractory to treatment
             for manic symptoms by history.

          4. Subjects unresponsive to clozapine for treatment of mania.

          5. Subjects with a significant risk of committing suicide based on history, mental status
             examination, investigator's judgment, or C-SSRS answer of &quot;yes&quot; to question 4 or 5
             (current or within the last 90 days).

          6. Subjects with a current manic episode with a duration of &gt; 2 years.

          7. Subjects who currently (within the past month) meet DSM-IV-TR criteria for substance
             abuse or substance dependence; this includes the abuse of alcohol and benzodiazepines,
             but excludes the use of caffeine and/or nicotine.

          8. Subjects who have a history or evidence of a medical condition that would expose them
             to an undue risk of a significant adverse event (AE) or interfere with assessments of
             safety or efficacy during the course of the trial, including but not limited to
             hepatic, renal, respiratory, cardiovascular, endocrine, neurologic, hematologic, or
             immunologic disease as determined by the clinical judgment of the investigator.

          9. Subjects who are currently experiencing a mixed or a depressive episode (per DSM-IV-TR
             criteria).

         10. Subjects with a history of hypersensitivity to antipsychotic agents.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stacy Wu, MD</last_name>
    <role>Study Director</role>
    <affiliation>Otsuka Pharmaceutical Development and Commercialization, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Springdale</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Garden Grove</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>National City</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oceanside</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orange</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pico Rivera</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Temecula</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lauderhill</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Leesburg</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Melbourne</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oakland Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Smyrna</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hoffman Estates</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Flowood</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Charles</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jenkintown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wichita Falls</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chatham</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aizu Wakamatsu</city>
        <state>Fukusima</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sapporo</city>
        <state>Hokkaido</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Morioka</city>
        <state>Iwate</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kawasaki-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Yokohama</city>
        <state>Kanagawa</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kashihara</city>
        <state>Nara</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sakai-shi</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sakai</city>
        <state>Osaka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fukuoka</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Itabashi-bu</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kanzaki-gun</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Koriyama-shi</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kumamoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Okinawa</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shinjuku-ku</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tottori</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Toyama</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anyang-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jeju-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gdynia</city>
        <state>Pomorskie</state>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bydgoszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chelmno</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Choroszcz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Targoviste</city>
        <state>Dyambovita</state>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bucharest</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Judet Lasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Keelung City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Taouyuan County</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>March 26, 2012</study_first_submitted>
  <study_first_submitted_qc>March 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2012</study_first_posted>
  <results_first_submitted>September 1, 2017</results_first_submitted>
  <results_first_submitted_qc>July 24, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 24, 2018</results_first_posted>
  <disposition_first_submitted>March 10, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>March 10, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">March 13, 2017</disposition_first_posted>
  <last_update_submitted>July 24, 2018</last_update_submitted>
  <last_update_submitted_qc>July 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aripiprazole</keyword>
  <keyword>Intramuscular (IM) Depot</keyword>
  <keyword>Bipolar</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aripiprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This trial was conducted in 1175 subjects (including 444 screen failures) at 103 trial sites in the following 7 countries: Canada, Japan, Republic of Korea, Poland, Romania, Taiwan, and the United States (US).</recruitment_details>
      <pre_assignment_details>The trial consisted of a screening phase and 4 phases. In Conversion, Oral Stabilization and IM Depot Stabilization Phases, there was a single treatment group. In Double-blind, Placebo-controlled Phase, there were 2 treatment groups. All Outcome Measures were assessed in the Double-blind, Placebo-controlled Phase of the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Conversion Phase.</title>
          <description>During the Oral Conversion Phase, subjects were cross-titrated from other antipsychotics to oral non-generic aripiprazole monotherapy.</description>
        </group>
        <group group_id="P2">
          <title>Oral Aripiprazole Stabilization Phase.</title>
          <description>During the Oral Stabilization Phase, subjects were stabilized on an oral dose of aripiprazole. 632 subjects entered the Oral Stabilization Phase (367 subjects entered from the Conversation Phase and 265 subjects entered the Oral Stabilization Phase directly).</description>
        </group>
        <group group_id="P3">
          <title>Intramuscular (IM) Depot Stabilization Phase.</title>
          <description>During the Depot Stabilization Phase, subjects were stabilized on aripiprazole IM depot. The subjects were assigned to aripiprazole IM depot in the IM Depot Stabilization Phase for a minimum of 12 weeks and a maximum of 28 weeks. To proceed to the Double-blind, Placebo-controlled Phase, subjects were required to meet all the protocol-defined stability criteria for a minimum of 8 consecutive weeks (4 consecutive biweekly visits).</description>
        </group>
        <group group_id="P4">
          <title>Double-blind Placebo-controlled Phase - Aripiprazole IM Depot.</title>
          <description>Subjects received aripiprazole 300 mg or 400 mg depot intramuscularly up to 52 weeks. A total of 266 subjects entered Double-blind Placebo-controlled phase. Of the 266 subjects, 133 were randomized to aripiprazole IM depot treatment. Since one subject withdrew consent to participate prior to receiving an injection, only 132 subjects received aripiprazole IM depot treatment.</description>
        </group>
        <group group_id="P5">
          <title>Double-blind Placebo-controlled Phase - Placebo.</title>
          <description>Subjects received placebo intramuscularly up to 52 weeks. A total of 266 subjects entered double-blind placebo-controlled Phase. Of the 266 subjects, 133 were randomized to placebo treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Conversion Phase.</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="466"/>
                <participants group_id="P2" count="0">There were no subjects in this reporting group in this phase of the study.</participants>
                <participants group_id="P3" count="0">There were no subjects in this reporting group in this phase of the study.</participants>
                <participants group_id="P4" count="0">There were no subjects in this reporting group in this phase of the study.</participants>
                <participants group_id="P5" count="0">There were no subjects in this reporting group in this phase of the study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="367"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="99"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Met withdrawal criteria</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="33"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawn by the investigator</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Oral Aripiprazole Stabilization Phase.</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">There were no subjects in this reporting group in this phase of the study.</participants>
                <participants group_id="P2" count="632">265 of the 632 subjects who started this phase entered the Oral Stabilization Phase directly.</participants>
                <participants group_id="P3" count="0">There were no subjects in this reporting group in this phase of the study.</participants>
                <participants group_id="P4" count="0">There were no subjects in this reporting group in this phase of the study.</participants>
                <participants group_id="P5" count="0">There were no subjects in this reporting group in this phase of the study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="425"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="207"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Met withdrawal criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="45"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="44"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="63"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawn by the investigator</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>IM Depot Stabilization.</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">There were no subjects in this reporting group in this phase of the study.</participants>
                <participants group_id="P2" count="0">There were no subjects in this reporting group in this phase of the study.</participants>
                <participants group_id="P3" count="425"/>
                <participants group_id="P4" count="0">There were no subjects in this reporting group in this phase of the study.</participants>
                <participants group_id="P5" count="0">There were no subjects in this reporting group in this phase of the study.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="266"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="159"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Met withdrawal criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="56"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor discontinued study</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="37"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawn by the investigator</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Double-blind, Placebo-controlled Phase</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0">Subjects were randomized to Aripiprazole IM Depot and placebo groups in this phase of the study</participants>
                <participants group_id="P4" count="133"/>
                <participants group_id="P5" count="133"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="64"/>
                <participants group_id="P5" count="38"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="69"/>
                <participants group_id="P5" count="95"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Recurrence of any mood episode with AE</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="16"/>
                <participants group_id="P5" count="33"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Met withdrawal criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>AE without recurrence of any moodepisode</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="7"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Sponsor discontinued study</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Recurrence of any mood episode withoutAE</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="19"/>
                <participants group_id="P5" count="35"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline characteristics were presented for the subjects randomized to Double-blind Placebo-controlled Phase. The Double-blind, Placebo-controlled Phase Efficacy Sample consisted of all randomized subjects who received at least 1 injection of IMP and had at least 1 post-baseline efficacy assessment.</population>
      <group_list>
        <group group_id="B1">
          <title>Aripiprazole Depot</title>
          <description>Subjects received aripiprazole 300 mg or 400 mg depot intramuscularly up to 52 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Subjects received placebo intramuscularly up to 52 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="133"/>
            <count group_id="B2" value="133"/>
            <count group_id="B3" value="266"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="133"/>
                    <measurement group_id="B2" value="132"/>
                    <measurement group_id="B3" value="265"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.6" spread="10.8"/>
                    <measurement group_id="B2" value="40.6" spread="11.2"/>
                    <measurement group_id="B3" value="40.6" spread="11.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="153"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Korea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Romania</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="102"/>
                    <measurement group_id="B3" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age at first manic episode (years)</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.2" spread="10.3"/>
                    <measurement group_id="B2" value="24.8" spread="9.9"/>
                    <measurement group_id="B3" value="25.0" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of mood episodes past 12 months</title>
          <units>Mood episodes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.2" spread="1.2"/>
                    <measurement group_id="B2" value="2.2" spread="1.1"/>
                    <measurement group_id="B3" value="2.2" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of disease prior to enrollment (years)</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.1" spread="9.2"/>
                    <measurement group_id="B2" value="13.6" spread="9.8"/>
                    <measurement group_id="B3" value="12.9" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of prior hospitalizations for a mood episode</title>
          <units>Prior hospitalization for mood episode</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.5" spread="3.9"/>
                    <measurement group_id="B2" value="3.5" spread="4.1"/>
                    <measurement group_id="B3" value="3.5" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Young-Mania Rating Scale (YMRS) Total Score</title>
          <description>The YMRS consisted of 11 items to assess the core symptoms of mania. Four items (irritability, speech, content, and disruptive-aggressive behavior) were graded on a scale of 0 to 8 (a higher score indicated increased severity) and 7 items (elevated mood, increased motor activity/energy, sexual interest, sleep, language-thought disorder, appearance, and insight) were graded on a scale of 0 to 4 (a higher score indicated increased severity). The scores from 11 items were summed to a total score ranging from 0 to 60 (higher score indicated greater severity of symptoms).</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.9" spread="3.5"/>
                    <measurement group_id="B2" value="2.6" spread="3.0"/>
                    <measurement group_id="B3" value="2.8" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Montgomery Asberg Depression Rating Scale (MADRS) Total Score</title>
          <description>The MADRS measured the depression level of a participant. This scale consisted of 10 items (reported sadness, apparent sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts), each with 7 defined grades of severity graded on a scale of 0 to 6 (a higher score indicated increased severity) . The overall total score was 0 to 60; 0, no depression; 60, severely depressed. The missing score for any one item resulted in a missing MADRS total score.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3.0" spread="3.4"/>
                    <measurement group_id="B2" value="2.4" spread="3.4"/>
                    <measurement group_id="B3" value="2.7" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical Global Impressions - Bipolar Version Severity (CGI-BP-S) - Mania</title>
          <description>CGI-BP-S assessed the subject’s severity of Illness (mania) based on a 7-point scale ranging from 1 (normal/ not ill at all) to 7 (very severely ill).</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.5" spread="0.7"/>
                    <measurement group_id="B2" value="1.4" spread="0.6"/>
                    <measurement group_id="B3" value="1.5" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time From Randomization to Recurrence of Any Mood Episode During Double-bind Placebo-controlled Phase.</title>
        <description>This endpoint was defined as meeting any of the following criteria:
Hospitalization for any mood episode OR
Any of the following:
YMRS total score ≥ 15 OR
MADRS total score ≥ 15 OR
CGI-BP-S score &gt; 4 (overall score) OR
SAE of worsening disease (bipolar I disorder) OR
Discontinuation due to lack of efficacy or discontinuation due to an AE of worsening disease OR
Clinical worsening with the need for treatment of symptoms of an underlying mood disorder by addition of a mood stabilizer, antidepressant treatment, antipsychotic medication, or increase greater than the allowed benzodiazepine doses, or
Active suicidality, which is defined as a score of 4 or more on the MADRS item 10 OR an answer of &quot;yes&quot; on question 4 or 5 on the C-SSRS.
The time to event is presented in the following table.</description>
        <time_frame>Baseline of the Double-blind, Placebo-controlled Phase Up to the end of the study (Week 52).</time_frame>
        <population>All randomized subjects who received at least one injection of investigational medicinal product (IMP) and had at least one post-baseline efficacy assessment in the Double-blind, Placebo-controlled Phase, eg, modified intent-to-treat (ITT) population.</population>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole IM Depot</title>
            <description>Subjects received aripiprazole 300 mg or 400 mg depot intramuscularly up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects received placebo intramuscularly up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Randomization to Recurrence of Any Mood Episode During Double-bind Placebo-controlled Phase.</title>
          <description>This endpoint was defined as meeting any of the following criteria:
Hospitalization for any mood episode OR
Any of the following:
YMRS total score ≥ 15 OR
MADRS total score ≥ 15 OR
CGI-BP-S score &gt; 4 (overall score) OR
SAE of worsening disease (bipolar I disorder) OR
Discontinuation due to lack of efficacy or discontinuation due to an AE of worsening disease OR
Clinical worsening with the need for treatment of symptoms of an underlying mood disorder by addition of a mood stabilizer, antidepressant treatment, antipsychotic medication, or increase greater than the allowed benzodiazepine doses, or
Active suicidality, which is defined as a score of 4 or more on the MADRS item 10 OR an answer of &quot;yes&quot; on question 4 or 5 on the C-SSRS.
The time to event is presented in the following table.</description>
          <population>All randomized subjects who received at least one injection of investigational medicinal product (IMP) and had at least one post-baseline efficacy assessment in the Double-blind, Placebo-controlled Phase, eg, modified intent-to-treat (ITT) population.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Here NA means values which were not estimable. The values for median and its 95% confidence interval of time to recurrence were not estimable due to the number of subjects with event was low.</measurement>
                    <measurement group_id="O2" value="308" lower_limit="178" upper_limit="NA">Here NA means values which were not estimable. The upper limit of 95% confidence interval of time to recurrence was not estimable in Placebo arm due to the number of subjects with event was low.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Significance level 0.05.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt; 0.0001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.451</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.299</ci_lower_limit>
            <ci_upper_limit>0.678</ci_upper_limit>
            <estimate_desc>Using the Cox proportional hazards model with term for treatment group.
HR is estimated for Aripiprazole IM depot relative to Placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Using the Cox proportional hazards model with term for treatment group.</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>2.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.475</ci_lower_limit>
            <ci_upper_limit>3.34</ci_upper_limit>
            <estimate_desc>HR is estimated for Placebo relative to Aripiprazole IM depot.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Meeting Criteria for Recurrence of Any Mood Episode.</title>
        <description>To assess the proportion of subjects who met criteria for recurrence of any mood episode (manic, mixed or depressive). Hierarchical procedure was used to preserve the overall Type I error at 0.05.</description>
        <time_frame>Baseline of the Double-blind, Placebo-controlled Phase Up to the end of the study (Week 52).</time_frame>
        <population>All randomized subjects who received at least one injection of IMP and had at least one post-baseline efficacy assessment in the Double-blind, Placebo-controlled Phase, eg, modified ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole IM Depot</title>
            <description>Subjects received aripiprazole 300 mg or 400 mg depot intramuscularly up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects received placebo intramuscularly up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Meeting Criteria for Recurrence of Any Mood Episode.</title>
          <description>To assess the proportion of subjects who met criteria for recurrence of any mood episode (manic, mixed or depressive). Hierarchical procedure was used to preserve the overall Type I error at 0.05.</description>
          <population>All randomized subjects who received at least one injection of IMP and had at least one post-baseline efficacy assessment in the Double-blind, Placebo-controlled Phase, eg, modified ITT population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis for any mood episode</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Using a hierarchical procedure to preserve the overall Type I error rate at 0.05, after testing the primary outcome.</non_inferiority_desc>
            <p_value>&lt; 0.0001</p_value>
            <method>Fisher Exact</method>
            <param_type>Percentage Difference (Final Values)</param_type>
            <param_value>-24.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-36.7</ci_lower_limit>
            <ci_upper_limit>-12.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Randomization to Endpoint in the CGI-BP-S (Mania) Score.</title>
        <description>CGI-BP-S assessed the subject's severity of Illness (mania) based on a 7-point scale ranging from 1 (normal/ not ill at all) to 7 (very severely ill).</description>
        <time_frame>Baseline of the Double-blind, Placebo-controlled Phase up to the end of the study (Week 52).</time_frame>
        <population>All randomized subjects who received at least one injection of IMP and had at least one post-baseline efficacy assessment in the Double-blind, Placebo-controlled Phase, eg, modified ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole IM Depot</title>
            <description>Subjects received aripiprazole 300 mg or 400 mg depot intramuscularly up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects received placebo intramuscularly up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Randomization to Endpoint in the CGI-BP-S (Mania) Score.</title>
          <description>CGI-BP-S assessed the subject's severity of Illness (mania) based on a 7-point scale ranging from 1 (normal/ not ill at all) to 7 (very severely ill).</description>
          <population>All randomized subjects who received at least one injection of IMP and had at least one post-baseline efficacy assessment in the Double-blind, Placebo-controlled Phase, eg, modified ITT population.</population>
          <units>Units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.16" spread="0.058"/>
                    <measurement group_id="O2" value="0.27" spread="0.126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Using mixed model repeated measures (MMRM) analysis with a restricted maximum likelihood (REML) approach. Analyses included the categorically fixed effects of treatment, region, trial week, and treatment-by-week interaction, as well as the continuously fixed covariates of baseline-score-by-week interaction. An unstructured covariance structure was used to model the within-subject errors and Kenward-Rodger degree of freedom was used to test the fixed effects.</non_inferiority_desc>
            <p_value>= 0.0011</p_value>
            <method>Mixed model repeated measure analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.69</ci_lower_limit>
            <ci_upper_limit>-0.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time From Randomization to Recurrence Defined by Hospitalization for a Mood Episode.</title>
        <description>Analysis of time from randomization to recurrence defined by hospitalization for a mood episode (Double-blind, Placebo-controlled Phase efficacy sample).
Time to recurrence is presented in the following table.</description>
        <time_frame>Baseline of the Double-blind, Placebo-controlled Phase up to the end of the study (Week 52).</time_frame>
        <population>All randomized subjects who received at least one injection of IMP and had at least one post-baseline efficacy assessment in the Double-blind, Placebo-controlled Phase, eg, modified ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>Aripiprazole IM Depot</title>
            <description>Subjects received aripiprazole 300 mg or 400 mg depot intramuscularly up to 52 weeks.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects received placebo intramuscularly up to 52 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time From Randomization to Recurrence Defined by Hospitalization for a Mood Episode.</title>
          <description>Analysis of time from randomization to recurrence defined by hospitalization for a mood episode (Double-blind, Placebo-controlled Phase efficacy sample).
Time to recurrence is presented in the following table.</description>
          <population>All randomized subjects who received at least one injection of IMP and had at least one post-baseline efficacy assessment in the Double-blind, Placebo-controlled Phase, eg, modified ITT population.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="133"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" lower_limit="NA" upper_limit="NA">Here NA means values which were not estimable. The values for median and its 95% confidence interval of time to recurrence were not estimable due to the number of subjects with event was low.</measurement>
                    <measurement group_id="O2" value="NA" lower_limit="NA" upper_limit="NA">Here NA means values which were not estimable. The values for median and its 95% confidence interval of time to recurrence were not estimable in Placebo arm due to the number of subjects with event was low.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>= 0.0002</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.137</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.04</ci_lower_limit>
            <ci_upper_limit>0.465</ci_upper_limit>
            <estimate_desc>Using the Cox proportional hazards model with term for treatment group.
HR is estimated for Aripiprazole IM depot relative to Placebo.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <non_inferiority_desc>Using the Cox proportional hazards model with term for treatment group.</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>7.313</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.151</ci_lower_limit>
            <ci_upper_limit>24.865</ci_upper_limit>
            <estimate_desc>HR is estimated for Placebo relative to Aripiprazole IM depot.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Any AEs were recorded from the signing of informed consent up to 52 weeks (end of the study).</time_frame>
      <desc>Safety analysis set (SAF): The SAF included all subjects who received at least one dose of trial medication in all phases of the study. Safety analysis results were reported for the safety populations.</desc>
      <group_list>
        <group group_id="E1">
          <title>Conversion Phase.</title>
          <description>During the Oral Conversion Phase, subjects were cross-titrated from other antipsychotics to oral non-generic aripiprazole monotherapy. Received Oral aripiprazole at a target starting dose of 15 mg/day.</description>
        </group>
        <group group_id="E2">
          <title>Oral Aripiprazole Stabilization Phase.</title>
          <description>Subjects received oral aripiprazole dose ranging from 15 mg to 30 mg daily.</description>
        </group>
        <group group_id="E3">
          <title>IM Depot Stabilization Phase.</title>
          <description>During the depot stabilization phase, subjects were stabilized on aripiprazole depot.</description>
        </group>
        <group group_id="E4">
          <title>Aripiprazole IM Depot- Double-blind, Placebo-controlled Phase.</title>
          <description>Subjects received IM depot aripiprazole 400 mg or 300 mg, once a month injection.</description>
        </group>
        <group group_id="E5">
          <title>Placebo-Double-blind, Placebo-controlled Phase.</title>
          <description>Subjects received IM Depot Placebo, once a month injection.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="614"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="132"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Vulval abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Accidental overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="459"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Extrapyramidal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Affect lability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Affective disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="459"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="614"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Bipolar I disorder</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="459"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="425"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Hypomania</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="459"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="614"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="425"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="132"/>
                <counts group_id="E5" events="10" subjects_affected="10" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="459"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="614"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="425"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Depressive symptom</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="614"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="614"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="459"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="614"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="425"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Renal Tubular Necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Pelvic adhesions</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="459"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="425"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="132"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="459"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="614"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="425"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="132"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (19.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="180" subjects_at_risk="459"/>
                <counts group_id="E2" subjects_affected="196" subjects_at_risk="614"/>
                <counts group_id="E3" subjects_affected="194" subjects_at_risk="425"/>
                <counts group_id="E4" subjects_affected="66" subjects_at_risk="132"/>
                <counts group_id="E5" subjects_affected="62" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="459"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="614"/>
                <counts group_id="E3" events="25" subjects_affected="22" subjects_at_risk="425"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="132"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="459"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="614"/>
                <counts group_id="E3" events="30" subjects_affected="22" subjects_at_risk="425"/>
                <counts group_id="E4" events="13" subjects_affected="10" subjects_at_risk="132"/>
                <counts group_id="E5" events="29" subjects_affected="13" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="459"/>
                <counts group_id="E2" events="23" subjects_affected="22" subjects_at_risk="614"/>
                <counts group_id="E3" events="47" subjects_affected="47" subjects_at_risk="425"/>
                <counts group_id="E4" events="31" subjects_affected="31" subjects_at_risk="132"/>
                <counts group_id="E5" events="25" subjects_affected="24" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Akathisia</sub_title>
                <counts group_id="E1" events="84" subjects_affected="76" subjects_at_risk="459"/>
                <counts group_id="E2" events="99" subjects_affected="94" subjects_at_risk="614"/>
                <counts group_id="E3" events="82" subjects_affected="74" subjects_at_risk="425"/>
                <counts group_id="E4" events="32" subjects_affected="27" subjects_at_risk="132"/>
                <counts group_id="E5" events="20" subjects_affected="17" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="64" subjects_affected="31" subjects_at_risk="459"/>
                <counts group_id="E2" events="21" subjects_affected="13" subjects_at_risk="614"/>
                <counts group_id="E3" events="12" subjects_affected="12" subjects_at_risk="425"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="132"/>
                <counts group_id="E5" events="10" subjects_affected="9" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="459"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="614"/>
                <counts group_id="E3" events="36" subjects_affected="30" subjects_at_risk="425"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="132"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="37" subjects_affected="35" subjects_at_risk="459"/>
                <counts group_id="E2" events="35" subjects_affected="34" subjects_at_risk="614"/>
                <counts group_id="E3" events="47" subjects_affected="41" subjects_at_risk="425"/>
                <counts group_id="E4" events="11" subjects_affected="10" subjects_at_risk="132"/>
                <counts group_id="E5" events="12" subjects_affected="10" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" events="45" subjects_affected="36" subjects_at_risk="459"/>
                <counts group_id="E2" events="34" subjects_affected="32" subjects_at_risk="614"/>
                <counts group_id="E3" events="25" subjects_affected="24" subjects_at_risk="425"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="132"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Until the information herein is released by Otsuka to the public domain, the contents of this document are Otsuka confidential information and should not be duplicated or re-distributed without prior written consent of Otsuka.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Joan Amatniek, Senior Director, Global Clinical Development</name_or_title>
      <organization>Otsuka Pharmaceutical Development &amp; Commercialization, Inc.</organization>
      <phone>(609) 512-4464</phone>
      <email>joan.amatniek@otsuka-us.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

